OA-48 Outcomes of Anti-BCMA CAR-T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma and CNS Involvement Based on a Multicenter Real-World Study With Extended Follow-Up

IF 4.1 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2026-09-01 Epub Date: 2026-09-22 DOI:10.1016/S2152-2650(26)03349-5

Sven Neubert, Markus Maulhardt, Inna Shaforostova, Stephan Bohl, Raphael Teipel, Natalie Schub, Anca-Maria Albici, Keven Hoerster, Amelie Boquoi, Snjezana Janjetovic, Elisa Kim Alves Carpinteiro, Tim Richardson, Thomas Pabst, Judith S. Hecker, Kim Agnes Munoz Alvarez, Justin Hasenkamp, Gerald Wulf, Georg Lenz, Hermann Einsele, Leo Rasche, Johannes Waldschmidt

引用次数: 0

查看原文本刊更多论文

基于延长随访的多中心真实世界研究，抗bcma car - t细胞治疗复发/难治性多发性骨髓瘤和中枢神经系统受累患者的OA-48结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.